Pnc9-MenC combination vaccine administered to infants at ages 2, 3, and 4 months demonstrated reduced group C meningococcal immunogenicity compared with MenC vaccine. The immunogenicity of concomitantly administered Hib and DTwP vaccines was also diminished. The Pnc9-MenC vaccine was safe and immunogenic for all contained pneumococcal serotypes.ReferenceImmunogenicity and Safety of a Combination Pneumococcal-Meningococcal Vaccine in Infants: A Randomized Controlled Trial Jim P. Buttery; Anna Riddell; Jodie McVernon; Tracey Chantler; Laura Lane; Jane Bowen-Morris; Linda Diggle; Rhonwen Morris; Anthony Harnden; Steven Lockhart; Andrew J. Pollard; Keith Cartwright; E. Richard Moxon JAMA. 2005;293:1751-1758. Abstract
CGD blog posts reflect the views of the authors, drawing on prior research and experience in their areas of expertise. CGD is a nonpartisan, independent organization and does not take institutional positions.